Revenir aux thèmes
Mycobacterium tuberculosis et tuberculose
Nouveaux antituberculeux
- Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis. Ibrahim M, Truffot-Pernot C, Andries K, Jarlier V, Veziris N. Am J Respir Crit Care Med. 2009; 180:553-7.
- A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis. Veziris N, Ibrahim M, Lounis N, Chauffour A, Truffot-Pernot C, Andries K, Jarlier V. Am J Respir Crit Care Med. 2009;179:75-9.
- K. Andries, P. Verhasselt, Pj. Guillemont, Hw Gohlmann, Jm Neefs, H. Winkler, J. Van Gestel, P. Timmermann, E. Zhu M. Lee, P. Williams, D. De Chaffoy, E. Huitric, S. Hoffner, E. Cambau, C. Truffot-Pernot, N. Lounis, V. Jarlier. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis Science 2005 ; 307 : 223-227.
- N. Veziris, V. Jarlier. Les nouveaux antituberculeux. BEH 2008 (10-11):72-74.
Infection expérimentale
- Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis. Ibrahim M, Truffot-Pernot C, Andries K, Jarlier V, Veziris N. Am J Respir Crit Care Med. 2009; 180:553-7.
- A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis. Veziris N, Ibrahim M, Lounis N, Chauffour A, Truffot-Pernot C, Andries K, Jarlier V. Am J Respir Crit Care Med. 2009;179:75-9.
Ibrahim M, Andries K, Lounis N, Chauffour A, Truffot-Pernot C, Jarlier V, Veziris N. Synergistic Activity of R207910 Combined with Pyrazinamide against Murine Tuberculosis. Antimicrob Agents Chemother. 2007 ;51(3):1011-1015.
Lounis N, Veziris N, Chauffour A, Truffot-Pernot C, Andries K, Jarlier V. Combinations of r207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration.Antimicrob Agents Chemother. 2006 ;50(11):3543-7.
Veziris N, Lounis N, Chauffour A, Truffot-Pernot C, Jarlier V. Efficient intermittent rifapentine-moxifloxacin-containing short-course regimen for treatment of tuberculosis in mice. Antimicrob Agents Chemother. 2005 ;49:4015-9.
N. Veziris, C. Truffot-Pernot, A. Aubry, V. Jarlier, N. Lounis. Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo. Antimicrob. Agents Chemother. 2003 ; 47 : 3117-3122.
N. Lounis, C. Maslo, C. Truffot-Pernot, J. Grosset, Jr. Boelaert. Impact of iron on the activity of isoniazid or ethambutol in the treatment of murine tuberculosis. Int J Tuberc Lung Dis 2003 ; 7 : 575-579.
N. Lounis, C. Truffot-Pernot, N. Veziris, V. Jarlier. Apports modèles expérimentaux dans le traitement curatif de la tuberculose. Méd. Mal. Infect 2003 ; 33 : 173s-179s.
haut de page
Mécanismes de résistance
- Purification, crystallization and preliminary X-ray diffraction experiments on the breakage-reunion domain of the DNA gyrase from Mycobacterium tuberculosis. Piton J, Matrat S, Petrella S, Jarlier V, Aubry A, Mayer C. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2009;65:1182-6.
- The pentapeptide repeat proteins MfpAMt and QnrB4 exhibit opposite effects on DNA gyrase catalytic reactions and on the ternary gyrase-DNA-quinolone complex. Mérens A, Matrat S, Aubry A, Lascols C, Jarlier V, Soussy CJ, Cavallo JD, Cambau E. J Bacteriol. 2009;191:1587-94
- Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. Matrat S, Aubry A, Mayer C, Jarlier V, Cambau E. Antimicrob Agents Chemother. 2008 Aug;52(8):2909-14.
- The peptidoglycan of stationary-phase Mycobacterium tuberculosis predominantly contains cross-links generated by L,D-transpeptidation. Lavollay M, Arthur M, Fourgeaud M, Dubost L, Marie A, Veziris N, Blanot D, Gutmann L, Mainardi JL. J Bacteriol. 2008 Jun;190(12):4360-6.
Molecular characterisation of isoniazid-resistant Mycobacterium tuberculosis isolated from new cases in Lagunes region (Côte d'Ivoire). N'Guessan KR, Dosso M, Ekaza E, Kouakou J, Jarlier V. Int J Antimicrob Agents. 2008 May;31(5):498-500.
- Veziris N, Martin C, Brossier F, Bonnaud F, Denis F, Aubry A. Treatment failure in a case of extensively drug-resistant tuberculosis associated with selection of a GyrB mutant causing fluoroquinolone resistance. Eur J Clin Microbiol Infect Dis. 2007;26:423-25.
F. Brossier, Veziris N, Truffot-Pernot C, Jarlier V, Sougakoff W. Performance of the genotype MTBDR line probe assay for detection of resistance to rifampin and isoniazid in strains of Mycobacterium tuberculosis with low- and high-level resistance. J Clin Microbiol. 2006 Oct ;44(10):3659-3564.
Aubry A, Fisher Ml, Jarlier V, Cambau E. First functional characterization of a singly expressed bacterial type II topoisomerase : The enzyme from Mycobacterium tuberculosis. Biochem Biophys Res Commun. 2006 ;348:158-165.
A. Aubry, N. Veziris, E. Cambau, C. Truffot-Pernot, V. Jarlier, L.M. Fisher. Novel gyrase mutations in Quinolone-resistant and –hypersusceptible clinical isolates of M. tuberculosis : functional analysis of mutant enzymes. Antimicrob. Agents Chemother. 2006 ; 50:104-112.
Petrella S, Cambau E, Chauffour A, Andries K, Jarlier V, Sougakoff W. Genetic basis for natural and acquired resistance to the diarylquinoline r207910 in mycobacteria. Antimicrob Agents Chemother. 2006 ;50:2853-6.
A. Aubry, X.S. Pan, M. Fischer, V. Jarlier, E. Cambau. Mycobacterium tuberculosis DNA gyrase : interaction with quinolones and correlation with antimycobacterial activity. Antimicrob Agents Chemother, 2004 ; 48:1281-1288.
W. Sougakoff, M. Rodrigue, C. Truffot-Pernot, M. Renard, N. Durin, M. Szpytma, R. Vachon, A. Troesch, V. Jarlier. Use of a high density DNA probe array for detecting mutations involved in rifampin resistance in Mycobacterium tuberculosis Clin Microbiol Infect. 2004 ; 10 : 289-294.
J. Dauendorffer, I. Guillemin, A. Aubry, C. Truffot-Pernot, W. Sougakoff, V. Jarlier, E. Cambau. Identification of mycobacterial species by PCR sequencing of quinolone resistance determining regions of DNA gyrase genes. J. Clin. Microbiol. 2003 ; 41 : 1311-1315.
haut de page
Epidémiologie - Diagnostic - Traitement
- Identification and genotyping of Mycobacterium tuberculosis complex species by use of a SNaPshot Minisequencing-based assay. Bouakaze C, Keyser C, de Martino SJ, Sougakoff W, Veziris N, Dabernat H, Ludes B. J Clin Microbiol. 2010;48:1758-66.
- Detection by GenoType MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant Mycobacterium tuberculosis complex isolates. Brossier F, Veziris N, Aubry A, Jarlier V, Sougakoff W. J Clin Microbiol. 2010 May;48(5):1683-9.
- Faut-il crainde la tuberculose à bacilles ultra-résistants en France ? (Editorial). N. Veziris, J. Robert. La Lettre de l'Infectiologue 2009;24:4-6.
- Performance of MTBDR plus for detecting high/low levels of Mycobacterium tuberculosis resistance to isoniazid. Brossier F, Veziris N, Jarlier V, Sougakoff W. Int J Tuberc Lung Dis. 2009;13:260-5.
- Cutaneous
miliary resistant tuberculosis in a patient infected with human immunodeficiency virus: case report and literature review. Regnier S, Ouagari Z, Perez ZL, Veziris N, Bricaire F, Caumes E. Clin Exp Dermatol. 2009;34:e690-2.
- Performance of MTBDR plus for detecting high/low levels of Mycobacterium tuberculosis resistance to isoniazid. Brossier F, Veziris N, Jarlier V, Sougakoff W. Int J Tuberc Lung Dis. 2009;13:260-5.
- Drug resistance and HIV co-infection among pulmonary tuberculosis patients in Haiphong City, Vietnam. PM. Khuê, TQ. Phuc, NV. Hung, V. Jarlier, J. Robert. Int J Tuberc Lung Dis. 2008 Jul;12(7):763-768.
- Evaluation of data quality in a laboratory-based surveillance of M. tuberculosis drug resistance and impact on the prevalence of resistance: France, 2004. P. M. Khuê, A. Mallet, V. Veziris, V. Jarlier, J. Robert, for the Azay-Mycobacteria Study Group. Epidemiol Infect. 2008 Sep;136(9):1172-8 .
-
J. Chemardin, MC. Paty, S. Renard-Dubois, N. Veziris, D. Antoine. Contact tracing of passengers exposed to an extensively drug-resistant tuberculosis case during an air flight from Beirut to Paris, October 2006. Euro Surveill. 2007 Dec 6;12(12).
- P. M. Khuê, C. Truffot-Pernot, J. Texier-Maugein, V. Jarlier, J. Robert. A 10-year prospective surveillance of Mycobacterium tuberculosis drug resistance in France 1995-2004. Eur Respir J 2007 ;30 :937-944.
- Veziris N, Martin C, Brossier F, Bonnaud F, Denis F, Aubry A. Treatment failure in a case of extensively drug-resistant tuberculosis associated with selection of a GyrB mutant causing fluoroquinolone resistance. Eur J Clin Microbiol Infect Dis. 2007;26:423-25.
- Uffredi M-L, C. Truffot-Pernot, B. Dautzenberg, M. Renard, V. Jarlier, J. Robert. An intervention programme for the management of multidrug-resistant tuberculosis in France. Int J Antimicrob Agent 2007 ;29:434-39.
-
J. Robert, N. Veziris, C. Truffot-Pernot, C. Grigorescu, V. Jarlier. Surveillance de la résistance aux antituberculeux en France : données récentes. Bulletin Epidemiologique Hebdomadaire 2007 (11):91-92.
E. Guerrin-Tran, J-M. Thiolet, C. Rousseau, S. Henry, C. Poirier, D. Che, J-M. Vinas, V. Jarlier, J. Robert and the AZAY-MYCOBACTERIA network. An evaluation of data quality in a network for surveillance of Mycobacterium tuberculosis resistance to antituberculosis drugs in Ile-de-France region-2001-2002. Eur J Epidemiol. 2006 ;21(10):783-785
E. Guerrin-Tran, J-M. Thiolet, C. Rousseau, S. Henry, C. Poirier, D. Che, J-M. Vinas, V. Jarlier, J. Robert et le réseau AZAY-MYCOBACTERIES. Evaluation de la qualité d’un réseau de surveillance de la tuberculose résistante en Ile-de-France en 2001-2002 (réseau Azay-Mycobactéries). Bulletin Epidemiologique Hebdomadaire 2006 (13):90-93.
J. Cailhol, D. Che, V. Jarlier, B. Decludt, J. Robert. Incidence of tuberculous meningitis in France in 2000 : a capture-recapture analysis. Int J. Tuberc. Lung. Dis. 2005 ; 9:803-808.
La tuberculose multirésistante en France : surveillance et prise en charge, 1992-2002. J. Robert, N. Veziris, C. Truffot-Pernot, C. Grigorescu, V. Jarlier. BEH 2005 (17-18):78-80.
N. Valin, F. Antoun, C. Chouaid, M. Renard, B. Dautzenberg, V. Lalande, B. Ayache, P. Morin, W. Sougakoff, Jm. Thiolet, C. Truffot-Pernot, V. Jarlier, B. Decludt. Outbreak of tuberculosis in a migrants’shelter, Paris France, 2002. Int. J. Tuberc. Lung Dis. 2005 ;9 : 528-533.
B. Dautzenberg, N. Veziris. Recommandations sur la prise en charge de la tuberculose en France. Société de Pneumologie de Langue Française. mt pédiatrie, 2004 : n° 2, mars-avril.
N. Veziris, A. Aubry, W. Sougakoff, C. Truffot-Pernot, V. Jarlier. Place des outils moléculaires dans le diagnostic, le traitement et l’épidémiologie des infections à mycobactéries. Med. Trop. 2004 ; 64 : 243-250.
N. Veziris, V. Jarlier. Nouveaux de diagnostic de la tuberculose : la révolution n’est pas achevée. Rev. Mal. Respir. 2004 ; 21 : 897-899.
J. Robert, D. Trystram, C. Truffot-Pernot, V. Jarlier. Multidrug-resistant tuberculosis : eight years of surveillance in France. Eur. Respir. J. 2003 ; 22 : 833-837.
N. Veziris, J. Robert. Tuberculose multirésistante : prise en charge. Management of multidrug-resistant tuberculosis. La Lettre de l’Infectiologue. 2003 ;18:186-191.
J. Robert, D. Trystram, C. Truffot, J. Grosset. La multirésistance (MDR) de Mycobacterium tuberculosis aux antibiotiques en France depuis 1992. Méd. Mal. Infect 2003 ; 33 : 183s-187s.
haut de page